894,578 Halozyme Therapeutics, Inc. $HALO Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,616,472 shares of the biopharmaceutical company’s stock after selling 894,578 shares during the period. William Blair Investment Management LLC owned 1.42% of Halozyme Therapeutics worth $178,459,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. Allworth Financial LP lifted its position in Halozyme Therapeutics by 3.5% during the 3rd quarter. Allworth Financial LP now owns 38,995 shares of the biopharmaceutical company’s stock worth $4,305,000 after acquiring an additional 1,331 shares during the period. R Squared Ltd purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $225,000. Fifth Third Bancorp grew its stake in shares of Halozyme Therapeutics by 52.3% in the 3rd quarter. Fifth Third Bancorp now owns 145,756 shares of the biopharmaceutical company’s stock valued at $16,091,000 after purchasing an additional 50,075 shares during the last quarter. Maryland State Retirement & Pension System increased its holdings in shares of Halozyme Therapeutics by 20.9% in the third quarter. Maryland State Retirement & Pension System now owns 7,382 shares of the biopharmaceutical company’s stock valued at $815,000 after purchasing an additional 1,275 shares during the period. Finally, Ritholtz Wealth Management increased its holdings in shares of Halozyme Therapeutics by 17.3% in the third quarter. Ritholtz Wealth Management now owns 6,570 shares of the biopharmaceutical company’s stock valued at $725,000 after purchasing an additional 971 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $82,482,605.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares of the company’s stock, valued at $6,339,313.86. The trade was a 24.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 124,226 shares of company stock valued at $13,370,893. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $100.27 on Monday. The firm’s fifty day simple moving average is $114.56 and its 200-day simple moving average is $85.51. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50. The stock has a market cap of $11.43 billion, a PE ratio of 25.51, a price-to-earnings-growth ratio of 0.38 and a beta of 0.92. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The business’s revenue for the quarter was up 39.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.72 earnings per share. Analysts expect that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a research report on Friday, November 6th. JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. TD Cowen raised their target price on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b+)” rating in a report on Monday, November 9th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Hold” and a consensus target price of $108.18.

Check Out Our Latest Report on HALO

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Further Reading

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.